BACE1 Expression Is Required for Proper Synaptic Vesicle Dynamics in the Hippocampus

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• Beta-secretase 1 (BACE1) cleaves amyloid precursor protein, producing β-amyloid peptides central to Alzheimer's disease (AD).
• BACE1 inhibition is a therapeutic strategy for AD, but clinical trials show limited efficacy.
• Previous studies indicate BACE1 inhibition impairs synaptic strength and density.

Purpose of the Study:

• To investigate the impact of BACE1 inhibition on synaptic vesicle exocytosis and endocytosis.
• To explore the molecular mechanisms underlying synaptic deficits caused by BACE1 deficiency.

Main Methods:

• Utilized a synapto-pHluorin mouse model to study activity-dependent synaptic vesicle dynamics.
• Performed transcriptomic analysis to identify gene expression changes in BACE1-deficient mice.
• Conducted pathway analysis to elucidate affected molecular signaling cascades.

Main Results:

• BACE1-deficient mice exhibit impaired synaptic release.
• Transcriptomic analysis revealed significant downregulation of genes involved in synapse structure and function.
• Pathway analysis indicated downregulation of the neurexin-neuroligin pathway, crucial for synaptic vesicle release.

Conclusions:

• BACE1 deficiency leads to deficits in synaptic vesicle exocytosis.
• Downregulation of key synaptic proteins, including those in the neurexin-neuroligin pathway, contributes to these deficits.
• These findings suggest potential mechanisms for the lack of efficacy in BACE1 inhibitor-based Alzheimer's disease therapies.